CH5424802
CH5424802 is an inhibitor of anaplastic lymphoma kinase (ALK) that displays anticancer chemotherapeutic and anti-metastatic activities against WT and L1196M mutant ALK. This compound is in clinical trials as a potential treatment for various cancers. CH5424802 induces regression of non-small cell lung cancer (NSCLC) cell metastasis in the brain in vivo, increasing survival rates. This compound displays efficacy in subjects resistant to crizotanib.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18849063
| Cas No. |
1256580-46-7 |
|---|---|
| Purity |
≥99% |
| Formula |
C30H34N4O2 |
| Formula Wt. |
482.62 |
| Synonym |
CH 5424802, Alectinib |
| Appearance |
White to off white powder |
Santarpia M, Altavilla G, Rosell R. Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer. Expert Rev Respir Med. 2015 Feb 5:1-14. [Epub ahead of print]. PMID: 25652176.
Kodama T, Hasegawa M, Takanashi K, et al. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol. 2014 Nov;74(5):1023-8. PMID: 25205428.
Kodama T, Tsukaguchi T, Yoshida M, et al. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett. 2014 Sep 1;351(2):215-21. PMID: 24887559.
Rossi A, Maione P, Sacco PC, et al. ALK inhibitors and advanced non-small cell lung cancer (review). Int J Oncol. 2014 Aug;45(2):499-508. PMID: 24889366.
